Tianeptine Addiction Treatment in Chiang Mai, Thailand
Tianeptine, sold as Zaza Red and similar gas station supplements, produces opioid-like dependence and a withdrawal pattern that involves both opioid and antidepressant discontinuation mechanisms. Jintara's medical detox program uses a slow medical taper, 24/7 nursing, and concurrent psychiatric support from the first day. 10 clients. 32 staff. 24/7 awake nursing.
Fully Licensed and Hospital Accredited
Tianeptine Is a Tricyclic Antidepressant That Activates Opioid Receptors at High Doses.
Tianeptine is a tricyclic antidepressant that activates opioid receptors at high doses, producing opioid-like effects despite its antidepressant classification. In countries where it is licensed as an antidepressant, it is prescribed at doses of 12.5mg three times daily. At the doses used recreationally, which can reach ten to thirty times the therapeutic range, the opioid receptor activity becomes dominant, and users experience euphoria, sedation, and the rapid tolerance cycle associated with opioid use.
Tianeptine is sold as a dietary supplement in many US states under names including Zaza Red, Zaza Blue, Za Za, and TD Red. Its legal grey-zone status as a supplement does not alter its receptor pharmacology, a point the FDA has warned consumers about directly. The compound acts on the brain's reward circuitry in the same way as opioids, and the dependence that follows is pharmacologically close to opioid dependence in most clinical respects.
What distinguishes tianeptine from standard opioids is the additional antidepressant discontinuation mechanism. When a person stops tianeptine after heavy use, they face both opioid withdrawal symptoms and antidepressant discontinuation symptoms at the same time. This dual mechanism is the primary reason tianeptine withdrawal is considered harder to manage than either mechanism alone.
Addiction to Tianeptine Can Develop Within Two to Four Weeks of Heavy Use.
Tianeptine addiction develops rapidly because the opioid receptor activation creates the same reinforcing cycle that drives opioid use disorder. A person who begins using tianeptine at supratherapeutic doses may develop physical dependence within two to four weeks. Tolerance escalates quickly, requiring larger doses to achieve the same effect, and the pattern of use shifts from recreational to compulsive.
The supplement framing of the product contributes to delayed recognition, because purchasers often start with the assumption that something sold at petrol stations and convenience stores cannot cause serious dependence. That framing is part of why tianeptine now sits within a broader category of emerging drug addiction, where substances not traditionally classified as drugs of abuse have developed significant misuse potential. Recognition tends to arrive late, once the daily dose has already climbed well beyond where it began.
By the time the dependence pattern becomes apparent, tolerance is often already significant and the dose required for normal functioning is well above the therapeutic range, a rise in tianeptine harm documented in CDC surveillance of tianeptine exposures. The people most affected are frequently those who began using the product to manage anxiety, low mood, or pain, and who did not recognise the shift into dependence until it was established.
Tianeptine Withdrawal Combines Opioid and Antidepressant Discontinuation in the Same Window.
Tianeptine withdrawal is characterised by two overlapping withdrawal syndromes occurring at the same time. The opioid component produces sweating, muscle aches, chills, nausea, vomiting, diarrhoea, severe anxiety, and insomnia, monitored clinically using the Clinical Opiate Withdrawal Scale (COWS). The antidepressant discontinuation component adds brain zaps, which are brief electric shock sensations, along with depersonalisation, mood instability that can be severe, crying episodes, and periods of dissociation.
Unlike heroin or prescription opioid withdrawal, tianeptine cessation adds an antidepressant discontinuation layer to the opioid component, which makes self-managed withdrawal particularly difficult to sustain. The two mechanisms do not resolve at the same rate. The opioid component tends to peak in the first 24 to 72 hours and begin resolving within a week, while the antidepressant discontinuation symptoms, particularly mood dysregulation and brain zaps, can persist for weeks after the opioid symptoms have resolved.
Abrupt cessation of high-dose tianeptine is not recommended. Unlike alcohol withdrawal, tianeptine withdrawal is rarely immediately life-threatening, but the severity of the dual-mechanism syndrome makes abrupt cessation extremely difficult to sustain and creates a significant risk of relapse within the first 24 to 48 hours without medical support.
The Two Withdrawal Mechanisms in Tianeptine Cessation
| Withdrawal component | What it produces | When it peaks and settles |
|---|---|---|
| Opioid component | Sweating, muscle aches, chills, nausea, severe anxiety, insomnia | Peaks in the first 24 to 72 hours and eases within a week |
| Antidepressant discontinuation | Brain zaps, mood crashes, depersonalisation, crying episodes | Can persist for weeks after the opioid symptoms have settled |
Opioid component
What it produces: Sweating, muscle aches, chills, nausea, severe anxiety, insomnia
When it peaks and settles: Peaks in the first 24 to 72 hours and eases within a week
Antidepressant discontinuation
What it produces: Brain zaps, mood crashes, depersonalisation, crying episodes
When it peaks and settles: Can persist for weeks after the opioid symptoms have settled
A Slow Medical Taper Addresses Both Withdrawal Mechanisms at Different Rates.
The clinical approach to tianeptine detox is a slow medical taper rather than abrupt cessation. Because tianeptine has opioid receptor activity, the taper draws on opioid withdrawal management, using COWS scoring and the vitals and withdrawal monitoring that track symptom severity and guide each dose reduction. Lertkhwan Sukpia, Jintara's on-site psychiatrist, assesses each client on arrival and establishes a taper protocol based on the dose history, use duration, and presenting symptoms.
Taper rate is individualised. Rapid reduction increases the risk of opioid-like withdrawal severity and may precipitate the antidepressant discontinuation symptoms too quickly for the client to manage. A slower reduction spread over one to three weeks allows the nervous system to adjust at a manageable pace, an approach consistent with established opioid detoxification guidance. Some clients require a longer taper depending on the dose at which they were using and the presence of co-occurring psychiatric conditions.
Methadone is used at Jintara during detox for the opioid withdrawal taper where clinically indicated. Jintara does not use or recommend maintenance medications such as naltrexone, acamprosate, or disulfiram after detox. The philosophy is stabilisation through a supervised taper, then therapy to address the psychological and behavioural drivers, with 24/7 awake nursing monitoring vital signs and symptom scores every one to two hours during the acute phase.
Psychiatric Support Addresses Mood Dysregulation as a Distinct Clinical Priority.
The antidepressant discontinuation component of tianeptine withdrawal requires psychiatric expertise that sits alongside, not after, the medical taper. It intersects directly with the dual diagnosis work that runs through the program, because the anxiety or depression a person was managing with tianeptine does not disappear when the drug does. Mood dysregulation during tianeptine cessation can be severe enough to create a risk of self-harm, and that risk is distinct from the standard anxiety and discomfort of opioid withdrawal.
Denise O'Leary, Jintara's Clinical Director, puts the baseline plainly. Pretty much everybody, without exception, comes in with some form of anxiety or depression, and it just seems to go with addiction. For tianeptine clients, that baseline is compounded by the discontinuation syndrome itself, which is why psychiatric involvement does not end at the intake assessment.
Clients requiring medication adjustment during the taper may have five to seven additional psychiatric consultations, included in the program fee rather than charged separately as at many competing facilities. Where a client's mood deteriorates significantly during the taper, psychiatric medication to stabilise the antidepressant discontinuation component may be introduced where clinically indicated. The threshold for hospital escalation is low, and Bangkok Hospital Chiang Mai and RAM Hospital are both confirmed transfer partners.
“Getting someone through withdrawal is one part of treatment. Understanding why they were using is the other part, and that work starts on day one.
Jintara's Day 2 Diagnostic Workup Identifies Health Conditions That Affect the Taper.
Every client admitted to Jintara attends a full medical workup at hospital on the second day, paid for by the facility. The Day 2 diagnostic workup includes a full blood spectrum, liver function tests, kidney function, EKG, and chest X-ray. For tianeptine clients, this workup matters because the opioid receptor activity of tianeptine at high doses can mask or interact with pre-existing cardiac, hepatic, or neurological conditions.
Liver function testing matters because tricyclic compounds are metabolised in the liver. Impaired liver function slows drug clearance, which means the same dose has a longer and more potent effect, so the taper rate and dose intervals are adjusted based on the workup findings. Cardiac assessment is relevant because opioid receptor activity at high doses carries cardiac load during the withdrawal phase, and EKG findings may prompt closer cardiac monitoring during the acute taper window.
Kidney function affects medication clearance across the taper period, and where kidney disease is identified, dose intervals are extended and electrolyte panels repeated more frequently. As Darren Lockie puts it, the workup regularly surfaces things that have not been dealt with, including quite a few liver issues picked up over the years.
Therapy Begins on Day One at Jintara, Running Concurrently With the Medical Taper.
Therapy begins on day one at Jintara, running concurrently with the medical taper rather than after it is complete. For tianeptine clients this matters because the psychological drivers of the dependence, including anxiety, stress, and mood dysregulation, are often the same conditions the person was managing with tianeptine before dependence developed.
Motivational interviewing is integrated into individual sessions throughout the taper period, supporting the client's ambivalence and helping them hold their reasons for change when withdrawal symptoms make those reasons harder to keep in view. The full treatment program runs on a non-12-step model, with CBT, DBT skills, and EMDR as the core modalities. Once the client is medically stable, that therapy work becomes the primary focus of the stay.
- Motivational interviewing: Woven into every individual session to support ambivalence and strengthen the client's own reasons for change.
- CBT and DBT modules: Cognitive behavioural therapy for the drivers of use, with abbreviated dialectical behaviour therapy skills for mood regulation.
- EMDR therapy: Used where trauma is a contributing factor, delivered by an EMDRIA-certified therapist.
- SMART Recovery framework: A secular, evidence-based peer support structure that replaces the 12-step model.
Denise O'Leary is direct about why this sequencing matters. A detox alone does not deal with the why, and most people who do detox alone end up relapsing quickly because they have not dealt with the reasons they were self-medicating.
Jintara Anchors the Clinical Answer on Tianeptine Addiction in Thailand.
Jintara has published clinical content on tianeptine addiction treatment grounded in receptor pharmacology and dual-mechanism withdrawal science. Based on available competitor research, no major provider in Thailand has published a tianeptine-specific page, which leaves an open field for a page written from clinical practice rather than marketing.
Tianeptine is not a niche concern. The page you are reading is written and reviewed by Jintara's clinical team, led by Lertkhwan Sukpia, who holds the clinical licence for the facility under Thailand's Ministry of Public Health. It is sold legally in multiple US states and is increasingly used in Asia and the Middle East, and Jintara's client base includes professionals from Australia, the UK, the United States, Canada, and Middle Eastern countries where polypharmacy presentations are common.
Lertkhwan Sukpia leads the psychiatric intake assessment for all admissions, including those presenting with tianeptine dependence. That combination of an on-site psychiatrist and a medical detox model is what makes a dual-mechanism substance manageable within a residential program rather than something that has to be referred out.
Brain Zaps Are a Real and Documented Symptom of Tianeptine Discontinuation.
Brain zaps are one of the most distressing and misunderstood aspects of tianeptine withdrawal, and they are a recognised symptom of antidepressant discontinuation syndrome. The symptom is a brief, involuntary sensation that clients describe as an electric shock, a flash of static electricity, or a sudden head-jolt, often accompanied by a moment of visual disruption or disorientation. For some clients, brain zaps occur dozens of times per day at peak intensity.
Brain zaps are not dangerous in themselves. They do not indicate a seizure, although clients who have not been told about them may find them frightening. The primary clinical concern is that untreated brain zaps, combined with sleep disruption and mood instability, create a pattern of cumulative distress that drives relapse. When clients understand that what they are experiencing is a predictable and time-limited symptom, they are far better placed to tolerate it.
Brain zap frequency and intensity typically reduce over one to four weeks following the end of the taper. For clients whose antidepressant discontinuation symptoms are severe, psychiatric medication may be used to smooth the resolution, and the clinical team monitors brain zap frequency as one indicator of discontinuation progress. Post-acute symptoms that persist beyond the acute window are addressed within the program's ongoing therapy structure.
Jintara Treats a Maximum of Ten Clients at Any Time, With a High Staff-to-Client Ratio.
Jintara accepts a maximum of ten clients at any one time and operates 32 staff for those ten clients, a ratio that exceeds any comparable facility in the Thailand private rehabilitation market. Every client has a private room, and the program fee covers medical detox, psychiatric assessment, 24/7 nursing, daily therapy, the Day 2 hospital workup, holistic sessions, and excursions, with no billed extras.
For a substance like tianeptine, where managing withdrawal requires psychiatric monitoring alongside medical supervision, the clinical structure matters. Clients are not managed by a rotating roster of unfamiliar staff, and the admissions process reviews each case before arrival to match it to the right clinical team. The same psychiatrist who conducts the intake assessment monitors progress through the taper, and the same therapy team that begins sessions on day one continues through to discharge planning.
The standard program duration is 30 days. Jintara's experience is that most clients benefit from extending beyond 30 days once detox is complete and the therapy work is underway, and extensions are available in increments as small as one week, with no locked-in commitment beyond the initial program. The average stay across all clients is approximately six weeks.
“We only treat substance use and mental health. We don't take ten kinds of clients. We take the one kind, and we do it well.
Talk with Our Admissions Team
Your enquiry is confidential and goes only to our admissions team.
Independently Verified
Jintara is accredited against Thailand’s national quality standard for drug treatment and rehabilitation facilities, jointly certified by the Healthcare Accreditation Institute, the body that accredits Thailand’s hospitals, with the Princess Mother National Institute on Drug Abuse Treatment and the Department of Medical Services, Ministry of Public Health. Certificate no. 25/2569, valid 20 May 2026 to 19 May 2029.
Common Questions About Tianeptine Addiction Treatment
Tianeptine is a tricyclic antidepressant that activates opioid receptors at high doses. It is sold in many US states as a dietary supplement under names like Zaza Red and Za Za. The informal name reflects the opioid-like effects at the doses most people who develop dependence are using, not the dose at which it would be prescribed as an antidepressant.
It is classified as a tricyclic antidepressant. At therapeutic doses of 12.5mg three times daily, it acts primarily on serotonin and may have modest antidepressant effects. At the supratherapeutic doses used recreationally, which can be ten to thirty times higher, the mu-opioid receptor activity is the dominant pharmacological effect. Both mechanisms are clinically relevant during withdrawal.
Physical dependence on tianeptine can develop within two to four weeks of heavy, high-dose use. Tolerance escalates rapidly because the opioid receptor response follows the same pattern as tolerance to opioids. Someone using the product daily for anxiety or pain relief may find their dose escalating significantly over a short period before recognising the pattern as dependence.
Clients describe tianeptine withdrawal as a combination of severe flu-like opioid symptoms, such as sweating, muscle aches, nausea, and insomnia, and a distinct antidepressant discontinuation component that includes mood crashes, brain zaps, and feelings of depersonalisation. The two syndromes overlap, and the antidepressant component can persist for several weeks after the opioid component begins to resolve.
Brain zaps are unpleasant but not dangerous in themselves. They are a recognised feature of antidepressant discontinuation syndrome and indicate that the nervous system is readjusting its neurotransmitter baseline after the tianeptine taper. They typically reduce in frequency and intensity over one to four weeks. For clients who find them distressing, psychiatric medication can help smooth the resolution period.
Jintara's taper protocols for tianeptine are derived from opioid withdrawal management and antidepressant discontinuation frameworks, both well established at the facility. The dual-mechanism withdrawal requires the combination of medical taper management and on-site psychiatric oversight that Jintara's model provides. Contact us to discuss your specific situation before admission.
Methadone is used at Jintara during detox for the opioid withdrawal taper on a case-by-case clinical basis. Whether it would be used in a specific tianeptine presentation depends on the dose history, the severity of the opioid component, and the assessment by Lertkhwan Sukpia on arrival. Jintara does not use methadone for maintenance after detox is complete.
For most people, mood improves significantly once the antidepressant discontinuation phase resolves and the nervous system recalibrates. The timeline varies. Acute mood instability typically peaks in the first one to two weeks and improves over the following two to four weeks. Residual low mood or anxiety may be addressed with psychiatric medication during this period where clinically indicated.
Therapy begins on day one at Jintara, not after the taper is complete. Individual sessions, group work, and holistic components run concurrently with the taper period. Once medically stable, the focus shifts to CBT for the underlying drivers of use, and EMDR therapy where trauma is a contributing factor.
The 30-day program costs USD 12,500, inclusive of medical detox, psychiatric assessment, 24/7 nursing, therapy, and all holistic components. There are no extra charges for psychiatric consultations or the Day 2 hospital medical workup. Contact the admissions team for current pricing and to discuss your situation before arrival.
Jintara treats tianeptine and Zaza Red dependence alongside opioid, benzodiazepine, and antidepressant-related addiction in Chiang Mai, Thailand.